Webinar Date/Time: Tue, Sep 26, 2023 11:00 AM EDT
Learn more about how the Prefabricated Modular Construction approach can improve your project delivery and reduce total cost of ownership.
Register Free: https://www.biopharminternational.com/bp_w/prefabricated-modular-construction
Event Overview:
Prefabricated modular construction has gained momentum in many industries around the globe -- but still experiences resistance and cause for concern from traditionalists within the biopharm industry. There have been many documented success stories which emphasize the benefits or the “Good” while the “Bad” is less publicized. This is typically based on myth or misperception, often due to lack of full understanding of the different options available and the true value the prefabricated approach can bring. There are also a fair number of “Not so Obvious” factors that should be considered when determining the best approach for constructing a new facility, which will be presented during the event.
Key Learning Objectives:
Who Should Attend:
Speaker:
Dennis Powers
Senior Vice President, Product & Strategy
G-CON
Dennis Powers is the Senior Vice President of Product & Strategy for G-CON Manufacturing and has over 25 years of experience working in the biopharmaceutical industry on both the manufacturing and supplier sides of the business. He has held positions in various technical and senior management functions in engineering, operations, project management, sales and marketing. Through his career, Dennis has worked closely with numerous companies across the industry to provide facility, process, and equipment solutions to address their needs. He is an active member of ISPE and PDA.
Dennis received his B.S. in Mechanical Engineering at the University of Delaware and his M.S. in Management from NYU Polytechnic University.
Register Free: https://www.biopharminternational.com/bp_w/prefabricated-modular-construction
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.